BeiGene, Ltd. American Depositary Shares
About: Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.
Employees: 10,000
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
142% more call options, than puts
Call options by funds: $66.1M | Put options by funds: $27.3M
108% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 26
56% more capital invested
Capital invested by funds: $6.69B [Q2] → $10.4B (+$3.73B) [Q3]
25% more funds holding in top 10
Funds holding in top 10: 8 [Q2] → 10 (+2) [Q3]
13% more funds holding
Funds holding: 197 [Q2] → 222 (+25) [Q3]
38% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 84
Research analyst outlook
We haven’t received any recent analyst ratings for ONC.
Financial journalist opinion
We haven’t received any recent news articles for ONC.